TheraTest

💡 A Different Kind of Testing & Revenue Partner💡

We’ve built a testing and revenue engine designed with one goal in mind, to help practices grow while improving patient outcomes.

Our approach focuses on a trifecta of value:

💰 Revenue: Generate $60K–$100K+ per provider annually with average margins exceeding 60%, no equipment or maintenance costs, and positive cash flow from day one.

🤝 Support: From turnkey implementation and regulatory support to EHR integration and onsite training, we handle the details so you can focus on your patients.

🧬 Clinical: Backed by an internal board of rheumatologists, our FDA-cleared, rheumatology-specific tests deliver proven efficacy and better outcomes.

TheraTest flips the script. It’s proof that when physicians lead innovation, everyone wins!

Thank you, NORM 2025! 🙏

We’re proud to be part of a community that values innovation, collaboration, and better outcomes for patients. Thank you to everyone who stopped by our booth to learn more about how TheraTest takes a different approach to testing. 💯

Until next time! 💙

🎉 The wait is over! We're excited to kick off the NORM 20205 Conference today! 🎉

Our team is on-site at the Ga***rd Palms Resort in Orlando and ready to connect with rheumatology professionals from across the country. 🌴✨

📍 Stop by booth to meet the team, explore our latest diagnostic innovations, and see how TheraTest is helping practices enhance revenue and deliver more precise, reliable results for their patients.

See you soon! 👋

🔍 𝗔 𝗻𝗲𝘄 𝘀𝘁𝘂𝗱𝘆 𝗵𝗮𝘀 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝗱 𝗽𝗹𝗮𝘀𝗺𝗮 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀 𝗽𝗿𝗲𝗱𝗮𝘁𝗶𝗻𝗴 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗼𝗻𝘀𝗲𝘁 𝗮𝗻𝗱 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗼𝗳 𝗿𝗵𝗲𝘂𝗺𝗮𝘁𝗼𝗶𝗱 𝗮𝗿𝘁𝗵𝗿𝗶𝘁𝗶𝘀 🔍

This kind of cutting-edge biomarker research is exactly what inspires our specialty testing services. We believe the future of rheumatology diagnostics lies in moving from “one-size-fits-all” to precision profiling of patients.

What this means for rheumatology practices?
✅ More actionable lab data to guide therapeutic decisions
✅ Better matching of patients to therapies early
✅ Potential for improved outcomes and fewer trial-and-error treatments

Read on here 👉 https://www.nature.com/articles/s41467-025-62032-1?

A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis - Nature Communications Rheumatoid arthritis (RA) mainly impacts the joints, which are difficult to sample, so identifying peripheral biomarkers may aid in diagnosis and treatment response predictions. Here the authors pursue a longitudinal study profiling plasma protein and use machine learning to train an algorithm for p...

We’re gearing up for the Organization of Rheumatology Management-NORM 2025 Annual Conference at the Ga***rd Palms Resort in Orlando, FL! 🌴☀️

The TheraTest team is passionate about raising the standard for diagnostic testing in rheumatology. Next week, we’ll be showcasing how our solutions deliver accuracy, reliability, and clarity for practices and patients alike.✨

📍 Visit our booth to see firsthand how we’re helping private practice make better decisions that enhance revenue and clinical outcomes.

👀 What’s next for RA therapy? 🔍

Spherix Global Insights finds that the “difficult-to-treat” RA population is driving much of the future innovation in care.

Key takeaways include:

✅ Nearly 1 in 5 RA patients are viewed as refractory.

✅ Oral TNF inhibitors are being hailed as a potential paradigm shift combining proven biology with patient convenience.

✅ Despite cost and biosimilar adoption, rheumatologists expect treatment strategies to evolve toward more personalized, mechanism-driven approaches over the next 3–5 years.

Check out the full report here👇 👇

https://www.globenewswire.com/news-release/2025/08/25/3138596/0/en/US-Rheumatologists-Point-to-Difficult-to-Treat-populations-Oral-Delivery-and-Novel-Mechanisms-as-the-Key-Drivers-of-Future-RA-Treatment-Evolution-According-to-Spherix-Global-Insigh.html?

US Rheumatologists Point to Difficult-to-Treat populations, Oral Delivery, and Novel Mechanisms as the Key Drivers of Future RA Treatment Evolution, According to Spherix Global Insights TNF biosimilars continue to expand, underscoring the tension between payer-driven cost pressures and pipeline-driven opportunity....

✨ 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁: 𝗧𝗼𝗻𝘆 𝗧𝗮𝘁𝗲, 𝗖𝗘𝗢 𝗼𝗳 𝗧𝗵𝗲𝗿𝗮𝗧𝗲𝘀𝘁 ✨

Tony is a scientist, Marine veteran, and entrepreneur whose unique journey has shaped both his leadership style and TheraTest’s mission to serve rheumatologists nationwide. 🤝 🩺

🔹 𝗙𝗿𝗼𝗺 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝘁𝗼 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗮𝗻𝗱 𝗯𝗮𝗰𝗸 𝗮𝗴𝗮𝗶𝗻
Tony began his career in microbiology and biochemistry, working in labs at the University of Illinois and Abbott Labs. He, then, shifted into finance as a commodities broker and options trader and eventually, his path led to leadership roles in sales and marketing at INCSTAR, and ICN Pharmaceuticals and TheraTest before becoming TheraTest's President and CEO.

🔹 𝗪𝗵𝘆 𝗧𝗵𝗲𝗿𝗮𝗧𝗲𝘀𝘁?
Tony helped purify the very antigens used to launch TheraTest in its earliest days. With firsthand knowledge of both the technology and the needs of rheumatologists, he envisioned a model where practices could access high-quality diagnostic kits while also recapturing significant revenue often lost to outside labs.

🔹 𝗜𝗺𝗽𝗮𝗰𝘁 & 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻
Under Tony’s leadership, TheraTest shifted focus from large reference labs to directly supporting rheumatologists. Today, practices across the country rely on TheraTest’s in-practice labs, not only for accurate, reliable results, but also for the financial stability they bring. As Tony puts it: “We can’t thank you enough” is the feedback that keeps us going.

🔹 𝗗𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝘀𝘂𝗰𝗰𝗲𝘀𝘀
A proud U.S. Marine Corps veteran, Tony instills the mindset of adapt, improvise, and overcome into his team. For him, success is simple: empowering his people to meet their goals while always putting the needs of rheumatology clients first.

🔹 𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗮𝗵𝗲𝗮𝗱
Currently, TheraTest is the only provider offering comprehensive in-practice lab solutions, serology, chemistry, hematology, ESR, and urinalysis designed specifically for rheumatology. For Tony, the mission is clear: strengthen independent practices, improve patient care, and fuel growth for the future.

🔹 𝗕𝗲𝘆𝗼𝗻𝗱 𝘁𝗵𝗲 𝗼𝗳𝗳𝗶𝗰𝗲
When he’s not leading TheraTest, Tony is a private pilot, scuba diver, competitive shooter, skier, and deep-sea fisherman. He also enjoys RV camping in national parks with his wife and three kids.

We’re looking forward to joining rheumatology leaders from across the country at the Coalition of State Rheumatology Organizations (CSRO) Advocacy Conference 9/12 & 9/13 at the Grand Hyatt in Dallas, Texas! 🇺🇸 🤠

Advocacy is at the heart of protecting independent rheumatology, and we’re we'll be there to share how the right partner can strengthen your practice financially, operationally, and clinically. 💰 📈 🧬

Let’s work together to ensure a future where rheumatologists can thrive and patients receive the care they deserve.

📲 Connect with us to set up a meeting!

💉 𝗜𝗻𝘂𝗹𝗶𝗻 𝗦𝘂𝗽𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗦𝗵𝗼𝘄𝘀 𝗣𝗿𝗼𝗺𝗶𝘀𝗲 𝗶𝗻 𝗥𝗵𝗲𝘂𝗺𝗮𝘁𝗼𝗶𝗱 𝗔𝗿𝘁𝗵𝗿𝗶𝘁𝗶𝘀 ✅

A randomized, triple-blind clinical trial found that daily supplementation with 10 g of inulin for eight weeks significantly improved several inflammation and disease markers in rheumatoid arthritis (RA) patients specifically reducing CRP, tender/swollen joint counts, DAS-28, HAQ scores, morning stiffness, and hand grip strength.



👉 Read the full article here: https://www.nature.com/articles/s41598-025-16611-3?

Inulin supplementation improves some inflammatory indices, clinical outcomes, and quality of life in rheumatoid arthritis patients - Scientific Reports Rheumatoid arthritis (RA) is a multifactorial autoimmune disease that causes joint dysfunction and is associated with changes in serum levels of some biomarkers. The present study investigated the effect of inulin supplementation on pain intensity, clinical outcomes, and quality of life in patients....